輸血傳播病原體新型檢測(cè)技術(shù)研究(核酸檢測(cè))。目前篩查血液中輸血傳播病原體(HIV/HBV/HCV/梅毒)主要采用ELISA方法檢測(cè)相關(guān)抗體或抗原。為了縮短窗口期,降低輸血相關(guān)傳染病的風(fēng)險(xiǎn),保障輸血安全,我國(guó)從2010年開始在血站進(jìn)行了核酸檢測(cè)試點(diǎn)工作。研究適合我國(guó)獻(xiàn)血者的高靈敏度、高特異性的HIV/HBV/HCV核酸檢測(cè)試劑,以及未來可能納入獻(xiàn)血者或獻(xiàn)漿者篩查的其他輸血傳播病原體的核酸檢測(cè)試劑,對(duì)于保障輸血安全具有重要意義。
輸血傳播病原體(HIV、HBV、HCV、B19等)在獻(xiàn)血及受血人群的流行病學(xué)及殘余風(fēng)險(xiǎn)研究。隨著臨床用血需求的增長(zhǎng),HIV、HBV、HCV、B19等原體從高危人群向普通人群的不斷擴(kuò)散,開展獻(xiàn)血者的流行病學(xué)研究——包括常規(guī)血液篩查病原體流行病學(xué)研究,新發(fā)再發(fā)病原體流行病學(xué)研究和細(xì)菌污染研究——的意義更顯得緊迫和重要,在調(diào)查了輸血相關(guān)傳染病的流行病學(xué)特征后,將能更好地掌握相關(guān)病原體的風(fēng)險(xiǎn)因素調(diào)查,提高血液性。
新型病毒滅活技術(shù)的研究。目前我國(guó)血液成分滅活技術(shù)僅有亞甲藍(lán)病毒滅活技術(shù),此方法只能應(yīng)用于血漿的病毒滅活,且滅活的病原體種類也有限,對(duì)細(xì)菌及部分無包膜病毒如HAV等無有效滅活作用。因此,開展新型病毒滅活技術(shù)研究尤為重要及迫切。
輸血傳播病原體病致病機(jī)理、持續(xù)感染、治療前療效預(yù)測(cè)、個(gè)體化治療及新型抗病毒藥物研究。肝炎病毒(如HBV/HCV等)可經(jīng)輸血傳播,導(dǎo)致病毒性肝炎,嚴(yán)重者發(fā)展成肝硬化或肝癌,但病毒與宿主相互作用,特別是病毒詳細(xì)的致病機(jī)理尚不完全明確,病毒性肝炎抗病毒治療效果也很不理想。開展肝炎病毒的致病機(jī)理、持續(xù)感染、治療前療效預(yù)測(cè)、個(gè)體化治療及新型抗病毒藥物研究對(duì)提高病毒性肝炎的治療效果、節(jié)約國(guó)家醫(yī)療資源具有重要意義。
目前平臺(tái)在研項(xiàng)目共計(jì)16項(xiàng),其中國(guó)際合作項(xiàng)目1項(xiàng),國(guó)家級(jí)項(xiàng)目4項(xiàng),省部級(jí)項(xiàng)目4項(xiàng),院校級(jí)項(xiàng)目4項(xiàng),以及其他主持和參與的項(xiàng)目5項(xiàng),如“協(xié)和創(chuàng)新團(tuán)隊(duì)”、科技部的“我國(guó)輸血傳播病原體核酸檢測(cè)關(guān)鍵技術(shù)研究”等項(xiàng)目,累計(jì)獲得科研經(jīng)費(fèi)超過1500萬元。平臺(tái)在2013年6月成功申報(bào)并獲準(zhǔn)建設(shè)四川省“輸血傳播疾病重點(diǎn)實(shí)驗(yàn)室”。兩年來平臺(tái)成員以第一作者或通訊作者共發(fā)表SCI文章8篇,其他文章7篇,編寫英文專著1部以及參與3本英文專著的編寫工作。
為了加強(qiáng)平臺(tái)的學(xué)術(shù)交流、營(yíng)造良好的學(xué)術(shù)氛圍,已聘請(qǐng)多位來自哈佛大學(xué)、多倫多大學(xué)等專家擔(dān)任客座教授,邀請(qǐng)國(guó)內(nèi)外的專家學(xué)者來所講學(xué),鼓勵(lì)平臺(tái)科研人員積極參加國(guó)際、國(guó)內(nèi)的學(xué)術(shù)會(huì)議,同時(shí)在平臺(tái)內(nèi)建立學(xué)術(shù)交流的固定機(jī)制(實(shí)驗(yàn)進(jìn)展、研究進(jìn)展匯報(bào)等);平臺(tái)主任陳利民教授應(yīng)邀在國(guó)際國(guó)內(nèi)學(xué)術(shù)大會(huì)上做大會(huì)主旨報(bào)告、特邀報(bào)告、分會(huì)主席10余次。
平臺(tái)在讀博士研究生4人,碩士研究生7人。
Research has been focusing on various transfusion-transmitted infectious diseases with funding from f 4 Natural Science Foundation of China (NSFC) grants, 4 provincial and ministrial grants, 4 Peking Union Medical College grants, and 5 grants from other sources.
15 papers, including 8 SCI papers with first- or senior-authorship in the past 2 years (2013-2014) was published. In addition, we also published an original book (248 pages in English) based on our research and as a contributor to write chapters for other 3 books.
In order to promote international academic exchange, we recruited 3 professors from University of Toronto and Harvard University to join us as visiting professors. We also invited many nationally- or internationally-known experts to give talks in their research field (10 speakers were invited in 2014 alone).
Professor Limin Chen was invited to deliver keynote, plenary speeches or act as session chairs in more than 10 national or international conferences in 2013-2014.
Provincial key laboratory in transfusion-transmitted diseases was approved to set up in our research platform.
PI簡(jiǎn)介
陳利民
北京協(xié)和醫(yī)學(xué)院海外引進(jìn)人才,“協(xié)和學(xué)者”特聘教授,四川省“百人計(jì)劃”入選者,四川省特聘專家,具有國(guó)外大學(xué)博士學(xué)位和博士后研究經(jīng)歷,多年來一直從事輸血傳播疾病,特別是丙肝病毒與宿主相互作用方面的研究。在丙肝個(gè)體化治療,干擾素治療前的療效預(yù)測(cè)和病毒耐藥分子機(jī)理等方面做出了一系列創(chuàng)新性的研究成果。目前擔(dān)任SCI雜志《Hepatitis Monthly》的副主編,7種英文雜志的編委。應(yīng)邀在國(guó)際國(guó)內(nèi)學(xué)術(shù)大會(huì)上做大會(huì)主旨報(bào)告、特邀報(bào)告、分會(huì)主席10余次。Tel:86-28-61648530 E-mail:limin_chen_99@yahoo.com
Dr. Limin Chen, professor ,principle investigator (PI) and head in the research center of the transfusion-transmitted infectious diseases (TTID), was recruited from the University of Toronto. He was selected as one of the “100 talents program” of Sichuan Province. Following his postdoctoral training in Merck Research labs (MRL, West Point) and MGH, Harvard Medical School, Dr. Chen has been doing research in the field of transfusion-transmitted infectious diseases, especially in HCV-host interactions. He made many breakthroughs in personalized medicine and molecular mechanisms of interferon resistance of HCV. Dr. Chen is an associate editor for one SCI journal and editorial board member for other 7 journals. He was invited to give keynote, plenary speeches or act as session chairs in more than 10 national or international conferences.
何苗
副研究員,碩士生導(dǎo)師,主要從事輸血安全領(lǐng)域的研究。研究方向包括人細(xì)小病毒B19在獻(xiàn)血人群的流行情況及其對(duì)我國(guó)血液安全的威脅,新發(fā)再發(fā)病原體的檢測(cè)方法建立以及這些病原體對(duì)我國(guó)血液安全的威脅,以及輸血傳播病原體的系統(tǒng)發(fā)育和群體遺傳學(xué)研究。Tel:86-28-61648552 E-mail:messa1022@126.com
Dr. Miao He, associate professor. Current research focuses on Phylogeography and population dynamics of Parvovirus B19 in Chinese blood donors as well as microbiome screening and emerging infectious pathogens ddentification in pooled plasma from Chinese blood products manufacturers.